Edition:
United States

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

171.55USD
12:45pm EDT
Change (% chg)

$1.13 (+0.66%)
Prev Close
$170.42
Open
$171.11
Day's High
$171.79
Day's Low
$170.85
Volume
110,447
Avg. Vol
407,146
52-wk High
$177.51
52-wk Low
$123.73

Latest Key Developments (Source: Significant Developments)

Shire Announces FDA Approval For Label Expansion Of Cinryze For Prevention Of Attacks In Pediatric HAE
Thursday, 21 Jun 2018 02:00am EDT 

June 21 (Reuters) - Shire PLC ::SHIRE ANNOUNCES FDA APPROVAL FOR LABEL EXPANSION OF CINRYZE FOR PREVENTION OF ATTACKS IN PEDIATRIC HAE.  Full Article

Takeda Says Entered Into Term Loan Credit Agreement For Up To $7.5 Billion For Shire Acquisition
Friday, 8 Jun 2018 02:01am EDT 

June 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SAYS ENTERED INTO TERM LOAN CREDIT AGREEMENT FOR UP TO $7.5 BILLION FOR SHIRE ACQUISITION.  Full Article

Takeda Pharmaceutical says execution of bridge loan agreement for Shire plc acquisition
Tuesday, 8 May 2018 02:38am EDT 

May 8(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it signed 364-Day Bridge Credit Agreement worth up to $30.85 billion for Shire plc acquisition on May 8 .  Full Article

Shire Says FDA Approves Vonvendi For Perioperative Management Of Bleeding In Adult Patients With Von Willebrand Disease
Tuesday, 17 Apr 2018 09:00am EDT 

April 17 (Reuters) - Shire PLC ::FDA APPROVES VONVENDI FOR PERIOPERATIVE MANAGEMENT OF BLEEDING IN ADULT PATIENTS WITH VON WILLEBRAND DISEASE.  Full Article

Takeda Responds to Media Reports About CEO's Comments On Possible Offer For Shire
Friday, 6 Apr 2018 12:35pm EDT 

April 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::STATEMENT REGARDING PRESS REPORTS.‍NOTES MEDIA REPORTS ABOUT COMMENTS ATTRIBUTED TO TAKEDA'S CEO CHRISTOPHE WEBER REGARDING COMPANY'S POSSIBLE OFFER FOR SHIRE PLC​.‍"CONFIRMS THAT WEBER'S COMMENTS WERE, HOWEVER, ALIGNED WITH STATEMENTS IN OUR PREVIOUS PRESS RELEASES"​.‍ PRIOR STATEMENTS "CLEARLY DEFINED STRATEGIC AND FINANCIAL OBJECTIVES CORE TO ITS DISCIPLINED APPROACH TO ACQUISITIONS".‍"ANY POTENTIAL OFFER FOR SHIRE, IF MADE, WOULD HAVE TO ALIGN WITH THE STRICT INVESTMENT CRITERIA"​.  Full Article

Shire Confirms It Has Not Received Approach From Takeda
Wednesday, 28 Mar 2018 08:30am EDT 

March 28 (Reuters) - Shire Plc ::REG-SHIRE PLC : STATEMENT RE POSSIBLE OFFER.‍NOTES ANNOUNCEMENT BY TAKEDA PHARMACEUTICAL COMPANY LIMITED​.SHIRE CONFIRMS THAT IT HAS NOT RECEIVED AN APPROACH FROM TAKEDA..  Full Article

Takeda Pharmaceutical Says Considers Making Approach To Shire On Possible Offer
Wednesday, 28 Mar 2018 05:23am EDT 

March 28 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::‍TAKEDA STATEMENT REGARDING SHIRE PLC​.‍CONFIRMS THAT IT IS CONSIDERING MAKING AN APPROACH TO SHIRE REGARDING A POSSIBLE OFFER .CONSIDERATION OF SUCH AN OFFER IS AT A PRELIMINARY AND EXPLORATORY STAGE AND NO APPROACH HAS BEEN MADE TO BOARD OF SHIRE.‍TAKEDA MUST, BY NO LATER THAN 5.00 P.M. ON 25 APRIL 2018, EITHER ANNOUNCE A FIRM INTENTION TO MAKE AN OFFER OR NOT​.  Full Article

Shire Says District Court Issues Ruling Finding Adderall XR Patents Infringed
Friday, 23 Mar 2018 05:15am EDT 

March 23 (Reuters) - Shire Plc ::DISTRICT COURT ISSUES RULING FINDING ADDERALL XR PATENTS INFRINGED.SHIRE DEVELOPMENT WELCOMES YESTERDAY'S FAVORABLE RULING AGAINST ABHAI IN CONNECTION WITH ANDA FOR A GENERIC VERSION OF SHIRE'S ADDERALL XR.ABHAI IS PROHIBITED FROM MARKETING ITS ANDA PRODUCT UNTIL EXPIRATION OF PATENTS.COURT SANCTIONED ABHAI FOR LITIGATION MISCONDUCT.JUDGE ISSUED A RULING HOLDING THAT PROPOSED ANDA FORMULATION INFRINGES CLAIMS OF PATENTS RE42,096 AND RE41,148.  Full Article

Shire Applies To Cease To Be A Reporting Issuer In Canada
Tuesday, 13 Mar 2018 10:02am EDT 

March 13 (Reuters) - Shire Plc ::SHIRE APPLIES TO CEASE TO BE A REPORTING ISSUER IN CANADA.SHIRE PLC - APPLIED TO AUTORITÉ DES MARCHÉS FINANCIERS FOR ORDER THAT CO MAY CEASE TO BE REPORTING ISSUER IN QUÉBEC, BRITISH COLUMBIA​.  Full Article

Caladrius Biosciences Acquires Exclusive Worldwide Rights To Data Set, Regulatory Filings For CD34+ Cell Therapy Program
Tuesday, 6 Mar 2018 08:00am EST 

March 6 (Reuters) - Caladrius Biosciences Inc ::CALADRIUS BIOSCIENCES ACQUIRES AN EXCLUSIVE LICENSE TO A LATE STAGE CD34+ CELL THERAPY PROGRAM FOR THE TREATMENT OF REFRACTORY ANGINA.CALADRIUS BIOSCIENCES INC - UNDER DEAL TERMS , ACQUIRED EXCLUSIVE WORLDWIDE RIGHTS TO DATA SET, REGULATORY FILINGS FOR CD34+ CELL THERAPY PROGRAM.CALADRIUS BIOSCIENCES INC - IN EXCHANGE, SHIRE WILL RECEIVE UNDISCLOSED UP-FRONT CONSIDERATION, MILESTONES AND A ROYALTY ON PRODUCT SALES.CALADRIUS BIOSCIENCES INC - ACQUIRED FROM SHIRE PLC AN EXCLUSIVE WORLDWIDE LICENSE TO DATA FROM A LATE STAGE CD34+ CELL THERAPY PROGRAM.  Full Article

Photo

Shire profit edges higher ahead of Takeda sale

LONDON Shire , the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations.